Patents by Inventor Pierfausto Seneci

Pierfausto Seneci has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TRIAZINE DERIVATIVES FOR THE TREATMENT OF TUMOURS AND NEURODEGENERATIVE DISORDERS
    Publication number: 20240327387
    Abstract: The present invention relates to compounds of Formula (I) to their pharmaceutical composition and their use as a medicament, in particular for the treatment and/or prevention of a tumour, viral infection, bacterial infection or neurodegenerative disease.
    Type: Application
    Filed: June 23, 2022
    Publication date: October 3, 2024
    Inventors: Luciana Marinelli, Daniela Arosio, Pierfausto Seneci
  • AMINOGUANIDINE HYDRAZONES AS RETROMER STABILIZERS USEFUL FOR TREATING NEUROLOGICAL DISEASES
    Publication number: 20220213030
    Abstract: The present invention relates to novel aminoguanidine hydrazone-derivatives of Formula (I) which are effective as retromer stabilizers and useful as neuroprotecting drugs. The invention also relates to pharmaceutical compositions comprising the compounds and their use in therapy and diagnostic.
    Type: Application
    Filed: April 1, 2020
    Publication date: July 7, 2022
    Inventors: Gianvito MARTINO, Luca MUZIO, Nilo RIVA, Davide GORNATI, Pierfausto SENECI, Simona Carmen ELEUTERI
  • Aza-tanshinone derivatives, process for their preparation and their use in therapy
    Patent number: 10689342
    Abstract: Object of the present invention are new aza-tanshinone derivatives, a method for their preparation and their use in therapy, particularly, but not limited to, as anti-tumor agents and anti-inflammatories. The invention comprises also the pharmaceutical compositions containing them.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: June 23, 2020
    Assignee: UNIVERSITA' DEGLI STUDI DI TRENTO
    Inventors: Alessandro Provenzani, Vito Giuseppe D'Agostino, Natthakan Thongon, Chiara Zucal, Preet Lal, Valentina Adami, Pierfausto Seneci, Leonardo Manzoni, Luciana Marinelli, Ettore Novellino, Marco Fragai, Claudio Luchinat, Linda Cerofolini, Carmelo Fuccio
  • AZA-TANSHINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THERAPY
    Publication number: 20190241516
    Abstract: Object of the present invention are new aza-tanshinone derivatives, a method for their preparation and their use in therapy, particularly, but not limited to, as anti-tumor agents and anti-inflammatories. The invention comprises also the pharmaceutical compositions containing them.
    Type: Application
    Filed: June 14, 2017
    Publication date: August 8, 2019
    Inventors: Alessandro PROVENZANI, Vito Giuseppe D'AGOSTINO, Natthakan THONGON, Chiara ZUCAL, Preet LAL, Valentina ADAMI, Pierfausto SENECI, Leonardo MANZONI, Luciana MARINELLI, Ettore NOVELLINO, Marco FRAGAI, Claudio LUCHINAT, Linda CEROFOLINI, Carmelo FUCCIO
  • Substituted thiazole or oxazole P2X7 receptor antagonists
    Patent number: 10167281
    Abstract: The present invention refers to novel substituted thiazole and oxazole compounds of formula (I) having P2X7 receptor (P2X7) antagonistic properties: The compounds are useful in the treatment or prophylaxis of diseases associated with P2X7 receptor activity in animals, in particular humans.
    Type: Grant
    Filed: June 18, 2017
    Date of Patent: January 1, 2019
    Assignee: Axxam S.P.A.
    Inventors: Paolo Pevarello, Stefan Lohmer, Chiara Llberati, Pierfausto Seneci, Cristina Pesenti, Adolfo Prandi
  • SUBSTITUTED THIAZOLE OR OXAZOLE P2X7 RECEPTOR ANTAGONISTS
    Publication number: 20170283409
    Abstract: The present invention refers to novel substituted thiazole and oxazole compounds of formula (I) having P2X7 receptor (P2X7) antagonistic properties: The compounds are useful in the treatment or prophylaxis of diseases associated with P2X7 receptor activity in animals, in particular humans.
    Type: Application
    Filed: June 18, 2017
    Publication date: October 5, 2017
    Applicant: Axxam S.P.A.
    Inventors: Paolo Pevarello, Stefan Lohmer, Chiara LIberati, Pierfausto Seneci, Cristina Pesenti, Adolfo Prandi
  • Homo- and heterodimeric SMAC mimetic compounds as apoptosis inducers
    Patent number: 9730976
    Abstract: The present invention relates to conformationally constrained homo- and heterodimeric mimetics of Smac with function as inhibitors of Inhibitor of Apoptosis Proteins (IAPs), the invention also relates to the use of these compounds in therapy, wherein the induction of apoptotic cell death is beneficial, especially in the treatment of cancer, alone or in combination with other active ingredients.
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: August 15, 2017
    Assignee: BioNTech AG
    Inventors: Pierfausto Seneci, Laura Belvisi, Federica Cossu, Domenico Delia, Carmelo Drago, Daniele Lecis, Stefano Maiorana, Leonardo Pierpaolo Manzoni, Eloise Mastrangelo, Mario Milani de Mayo de Mari, Paola Maria Chiara Perego, Francesca Vasile
  • Substituted thiazole or oxazole P2X7 receptor antagonists
    Patent number: 9718812
    Abstract: The present invention refers to novel substituted thiazole and oxazole compounds of formula (I) having P2X7 receptor (P2X7) antagonistic properties. The compounds are useful in the treatment or prophylaxis of diseases associated with P2X7 receptor activity in animals, in particular humans.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: August 1, 2017
    Assignee: Axxam S.P.A.
    Inventors: Paolo Pevarello, Stefan Lohmer, Chiara Llberati, Pierfausto Seneci, Cristina Pesenti, Adolfo Prandi
  • SUBSTITUTED THIAZOLE OR OXAZOLE P2X7 RECEPTOR ANTAGONISTS
    Publication number: 20170008883
    Abstract: The present invention refers to novel substituted thiazole and oxazole compounds of formula (I) having P2X7 receptor (P2X7) antagonistic properties. The compounds are useful in the treatment or prophylaxis of diseases associated with P2X7 receptor activity in animals, in particular humans.
    Type: Application
    Filed: February 4, 2015
    Publication date: January 12, 2017
    Applicant: Axxam S.P.A.
    Inventors: Paolo Pevarello, Stefan Lohmer, Chiara LIberati, Pierfausto Seneci, Cristina Pesenti, Adolfo Prandi
  • New Homo- and Heterodimeric SMAC Mimetic Compounds as Apoptosis Inducers
    Publication number: 20160317605
    Abstract: The present invention relates to conformationally constrained homo- and heterodimeric mimetics of Smac with function as inhibitors of Inhibitor of Apoptosis Proteins (IAPs), the invention also relates to the use of these compounds in therapy, wherein the induction of apoptotic cell death is beneficial, especially in the treatment of cancer, alone or in combination with other active ingredients.
    Type: Application
    Filed: July 21, 2016
    Publication date: November 3, 2016
    Applicant: BioNTech AG
    Inventors: Pierfausto Seneci, Laura Belvisi, Federica Cossu, Domenico Delia, Carmelo Drago, Daniele Lecis, Stefano Maiorana, Leonardo Pierpaolo Manzoni, Eloise Mastrangelo, Mario Milani de Mayo de Mari, Paola Maria Chiara Perego, Francesca Vasile
  • Homo- and heterodimeric SMAC mimetic compounds as apoptosis inducers
    Patent number: 9321808
    Abstract: The present invention relates to conformationally constrained homo- and heterodimeric mimetics of Smac with function as inhibitors of Inhibitor of Apoptosis Proteins (IAPs), the invention also relates to the use of these compounds in therapy, wherein the induction of apoptotic cell death is beneficial, especially in the treatment of cancer, alone or in combination with other active ingredients.
    Type: Grant
    Filed: February 20, 2012
    Date of Patent: April 26, 2016
    Assignee: BioNTech AG
    Inventors: Pierfausto Seneci, Laura Belvisi, Federica Cossu, Domenico Delia, Carmelo Drago, Daniele Lecis, Stefano Maiorana, Leonardo Pierpaolo Manzoni, Eloise Mastrangelo, Mario Milani de Mayo de Mari, Paola Maria Chiara Perego, Francesca Vasile
  • New Homo- and Heterodimeric SMAC Mimetic Compounds as Apoptosis Inducers
    Publication number: 20150119342
    Abstract: The present invention relates to conformationally constrained homo- and heterodimeric mimetics of Smac with function as inhibitors of Inhibitor of Apoptosis Proteins (IAPs), the invention also relates to the use of these compounds in therapy, wherein the induction of apoptotic cell death is beneficial, especially in the treatment of cancer, alone or in combination with other active ingredients.
    Type: Application
    Filed: February 20, 2012
    Publication date: April 30, 2015
    Applicants: Universita' Degli Studi Di Milano, Fondazione Cariplo, CISI Scrl, Fondazione IRCCS Istituto Nazionale dei Tumori
    Inventors: Pierfausto Seneci, Laura Belvisi, Federica Cossu, Domenico Delia, Carmelo Drago, Daniele Lecis, Stefano Maiorana, Leonardo Pierpaolo Manzoni, Eloise Mastrangelo, Mario Milani de Mayo de Mari, Paola Maria Chiara Perego, Francesca Vasile
  • SMAC mimetic compounds as apoptosis inducers
    Patent number: 8609685
    Abstract: The present invention relates to compounds conformationally constrained mimetics of Smac with function as inhibitors of Inhibitor of Apoptosis Proteins (IAPs), the invention also relates to the use of these compounds in therapy, wherein the induction of apoptotic cell death is beneficial, especially in the treatment of cancer, alone or in combination with other active ingredients.
    Type: Grant
    Filed: November 5, 2008
    Date of Patent: December 17, 2013
    Assignee: CISI SCRL
    Inventors: Carlo Scolastico, Leonardo Pierpaolo Manzoni, Pierfausto Seneci, Laura Belvisi, Domenico Delia, Martino Bolognesi, Eloise Mastrangelo, Mario De Mayo De Mari Milani, Ilaria Motto, Carmelo Drago
  • SMAC MIMETIC COMPOUNDS AS APOPTOSIS INDUCERS
    Publication number: 20100267692
    Abstract: The present invention relates to compounds conformationally constrained mimetics of Smac with function as inhibitors of Inhibitor of Apoptosis Proteins (IAPs), the invention also relates to the use of these compounds in therapy, wherein the induction of apoptotic cell death is beneficial, especially in the treatment of cancer, alone or in combination with other active ingredients.
    Type: Application
    Filed: November 5, 2008
    Publication date: October 21, 2010
    Inventors: Carlo Scolastico, Leonardo Pierpaolo Manzoni, Pierfausto Seneci, Laura Belvisi, Domenico Delia, Martino Bolognesi, Eloise Mastrangelo, Mario Milani, Ilaria Motto, Carmelo Drago
  • N-carbacycle monosubstituted indolocarbazoles as protein kinase inhibitors
    Patent number: 7262215
    Abstract: This invention relates to N-carbacycle monosubstituted indolocarbazole compounds. Furthermore, this invention relates to medicaments comprising N-carbacycle monosubstituted indolocarbazoles compounds and the use of such compounds for treating non-insulin dependent diabetes mellitus, acute stroke and other neurotraumatic injuries, for treating diabetes mellitus, as a chemotherapeutic for the treatment of various malignant diseases, for treating diseases caused by malfunctioning of specific signaling pathways, and for treating neurodegenerative diseases such as for example Alzheimer's disease.
    Type: Grant
    Filed: December 4, 2002
    Date of Patent: August 28, 2007
    Assignee: NAD AG
    Inventors: Heidi Sahagun-Krause, Olivier Thillaye Du Boullay, Valerie Thillaye Du Boullay, Laura Casiraghi, Hans-Wolfgang Klafki, Pierfausto Seneci, Tobias Braxmeier, Silvia Müller, Wolfgang Fr{hacek over (o)}hner, Barbara Monse, Sandra Gordon, Hanno M. Roder
  • N-carbacycle monosubstituted indolocarbazoles as protein kinase inhibitors
    Publication number: 20050075386
    Abstract: This invention relates to N-carbacycle monosubstituted indolocarbazole compounds. Furthermore, this invention relates to medicaments comprising N-carbacycle monosubstituted indolocarbazoles compounds and the use of such compounds for treating non-insulin dependent diabetes mellitus, acute stroke and other neurotraumatic injuries, for treating diabetes mellitus, as a chemotherapeutic for the treatment of various malignant diseases, for treating diseases caused by malfunctioning of specific signaling pathways, and for treating neurodegenerative diseases such as for example Alzheimer's disease.
    Type: Application
    Filed: December 4, 2002
    Publication date: April 7, 2005
    Inventors: Heidi Sahagun-Krause, Olivier Du Boullay, Valerie Du Boullay, Laura Casiraghi, Hans-Wolfgang Klafki, Pierfausto Seneci, Tobias Braxmeier, Silvia Muller, Wolfgang Frohner, Barbara Monse, Sandra Gordon, Hanno Roder
  • Basic proline-amide derivatives of GE 2270 and GE 2270-like antibiotics
    Patent number: 6143739
    Abstract: The present invention refers to basic amides derivatives of GE 2270 and GE 2270-like antibiotics of general formula (1), wherein the group GE represents the antibiotic core molecule. The amide derivatives of antibiotic GE 2270 of formula (I) are antimicrobial agents mainly active against gram positive bacteria.
    Type: Grant
    Filed: July 31, 1997
    Date of Patent: November 7, 2000
    Assignee: Biosearch Italia S.p.A.
    Inventors: Sergio Lociuro, Pierfausto Seneci, Ermenegildo Restelli, Romeo Ciabatti
  • Indole derivatives for the treatment of osteoporosis
    Patent number: 5985905
    Abstract: The invention relates to indole compounds, a process for preparing, pharmaceutical compositions containing the compounds and treating diseases associated with over activity of osteoclasts.
    Type: Grant
    Filed: May 5, 1999
    Date of Patent: November 16, 1999
    Inventors: Carlo Farina, Guy Marguerite Marie Gerard Nadler, Pierfausto Seneci
  • Basic oxazoline-amide derivatives of GE2270 and GE2270-like antibiotics
    Patent number: 5891869
    Abstract: The present invention refers to basic oxazoline-amide derivatives of GE 2270 and GE 2270-like antibiotics of general formula (I), wherein the group GE represents the antibiotic core molecule. The amide derivatives of antibiotic GE 2270 of formula (I) are antimicrobial agents mainly active against gram positive bacteria.
    Type: Grant
    Filed: July 31, 1997
    Date of Patent: April 6, 1999
    Assignee: Biosearch Italia, S.p.A.
    Inventors: Sergio Lociuro, Pierfausto Seneci, Romeo Ciabatti
  • Substituted alkylamide derivatives of teicoplanin
    Patent number: 5500410
    Abstract: The present invention is directed to new C.sup.63 amide derivatives of teicoplanin wherein the amide moiety is derived from a di- or poly-alkylamine, and to a process for preparing them. The derivatives are prepared by reacting a teicoplanin-like product with an active ester forming reagent such as chloroacetonitrile and then contacting said active ester with the appropriate di- or poly-alkylamine. The amide derivatives of the invention are active against gram positive and gram negative bacteria.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: March 19, 1996
    Assignee: Gruppo Lepetit S.p.A.
    Inventors: Adriano Malabarba, Pierfausto Seneci, Jurgen K. Kettenring, Romeo Ciabatti